Pancreatic cancer: Updates on translational research and future applications: Highlights from the "2013 ASCO gastrointestinal cancers symposium". san Francisco, CA, USA. january 24-26, 2013

Journal of the Pancreas

Volumn 14, Issue 2, 2013, Pages 145-148

  Sarris, Evangelos G ^a   Syrigos, Konstantinos N ^a   Saif, Muhammad Wasif ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Biological markers; Pancreatic neoplasms; Pharmacogenomics; Translational medical research

Indexed keywords

BRCA2 PROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; FRAGILE HISTIDINE TRIAD PROTEIN; GEMCITABINE; INTERLEUKIN 6; K RAS PROTEIN; NOTCH1 RECEPTOR; ONCOPROTEIN; PLATINUM COMPLEX; PROTEIN KINASE B BETA; PROTEIN P53; PROTEIN SWI; PROTEIN YKL 40; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER INJURY; MEDICAL SOCIETY; NONALCOHOLIC FATTY LIVER; ONCOGENE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHARMACOGENOMICS; PNPLA3 GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYMPOSIUM; TRANSLATIONAL RESEARCH;

ADENOCARCINOMA; GASTROENTEROLOGY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDICAL ONCOLOGY; PANCREATIC NEOPLASMS; PHARMACOGENETICS; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84875010821     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Nakamura K, Nagata C, Wada K, Tamai Y, Tsuji M, et al. Cigarette smoking and other lifestyle factors in relation to the risk of pancreatic cancer death: a prospective cohort study in Japan. Jpn J Clin Oncol 2011; 41: 225-231.
2. Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 779-792.
3. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011; 40: 339-351.
4. Johansen D, Stocks T, Jonsson H, Lindkvist B, Bjorge T, et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 2010; 19: 2307-2317.
5. Gapstur SM, Jacobs EJ, Deka A, McCullough ML, Patel AV, et al. Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch Intern Med 2011; 171: 444-451.
6. Wang W, Liao Z, Li G, Li ZS, Chen J, et al. Incidence of Pancreatic Cancer in Chinese Patients with Chronic Pancreatitis. Pancreatology 2011; 11: 16-23.
7. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218-1249.
8. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, et al. Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 2010; 30: 423-429.
9. Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, et al. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008; 26: 4557-4562.
10. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 27:495-522.
11. Strimpakos A, Hoimes C, Syrigos KN, Saif MW. Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes? Current Pharmacogenomics and Personalized Medicine 2010; 1: 73-88.
12. Mohammed Aly, Ibrahim Halil Sahin, Donghui Li, Mohamed Fahd Khalil, Ping Chang, et al. Pancreatic injury, genetic variation of PNPLA3, and risk of pancreatic cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 141)
13. Sookoian S, Pirola CJ. PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease. World J Gastroenterol 2012 Nov 14; 18(42):6018-26.
14. Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011 Sep; 31(8):1137-43.
15. Masakatsu Numata, Soichiro Morinaga, Takuo Watanabe, Hiroshi Tamagawa, Naoto Yamamoto, et al. The clinical significance of SWI/SNF complex in pancreatic cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 149)
16. Medina PP, Sanchez-Cespedes M. Involvement of the chromatin- remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics 2008 Mar-Apr; 3(2):64-8.
17. Vineet Sangar, Mark Ricigliano, Eileen Mary O'Reilly, Ghassan K. Abou-Alfa, Maeve Aine Lowery, et al. Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance. J Clin Oncol 30: 2012 (suppl 34; abstr 142)
18. Paul Basile, Isabelle iwanicki-Caron, Emmanuel Toure, Michel Antonietti, Stephane Lecleire, et al. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis. J Clin Oncol 30: 2012 (suppl 34; abstr 157)
19. Nicolai Aagaard Schultz, Ib Jarle Christensen, Jens Werner, Nathalia Giese, Benny Vittrup Jensen, et al. Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers. J Clin Oncol 30: 2012 (suppl 34; abstr 164)